Effect of SR121566A, a potent GP IIb-IIIa antagonist on platelet-mediated thrombin generation in vitro and in vivo

Thrombosis and Haemostasis

Volumn 79, Issue 2, 1998, Pages 383-388

  Herault, J P ^a   Peyrou, V ^a   Savi, P ^a   Bernat, A ^a   Herbert, J M ^a  

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 [[4 [4 (AMINOIMINOMETHYL)PHENYL] 2 THIAZOLYL](1 CARBOXYMETHYL 4 PIPERIDINYL)AMINO]PROPIONIC ACID; ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ARACHIDONIC ACID; COLLAGEN; FIBRINOGEN RECEPTOR ANTAGONIST; THROMBIN; THROMBOPLASTIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; AREA UNDER THE CURVE; ARTICLE; BLOOD CLOTTING; CONCENTRATION RESPONSE; CONTROLLED STUDY; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; PRIORITY JOURNAL; RABBIT; THROMBIN TIME; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE RICH PLASMA; THROMBOGENESIS; VEIN THROMBOSIS; VENOUS STASIS;

EID: 0031884176     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0037-1614996     Document Type: Article

References (30)

1. Walsh PM, Schmaier AH. Platelet-coagulant protein interactions. In: Hemostasis & Thrombosis: Basic principles and clinical practice. 3rd ed. Colman RW, Hirsh, J, Marder VJ, Salzman EW, eds. JB Lippicott Co, Philadelphia 1994; 629-51.
2. Hawiger J. Formation and regulation of platelet and fibrin hemostatic plug. Hum Pathol 1987; 18: 111-32.
3. Bevers EM, Comfurius P, Van Rijn JLML, Henker C, Zwaal RFA. Generation of prothrombin-converting activity and the exposure of phosphatidyl serine at the outer surface of platelets. Eur J Biochem 1982; 122: 429-36.
4. Bevers EM, Comfurius P, Zwaal RFA. Mechanisms involved in platelets procoagulant response. In: Mechanism of platelet activation and control. Authi KS et al., eds. Plenum Publishing Corp, New York 1994; 195-207.
5. Bernat A., Vallée E, Maffrand JP, Gordon JL. The role of platelets and ADP in experimental thrombosis induced by venous stasis in the rat. Thromb Res 1988; 52: 65-70.
6. Herbert, JM, Bernat A, Maffrand JP. Importance of platelets in experimental venous thrombosis in the rat. Blood 1992; 80: 2281-6.
7. Bernat A, Vallée E, Maffrand JP, Roncucci R. Antithrombotic effect of ticlopidine in a platelet-independent model of venous thrombosis: Thromb Res 1985; 37: 279-85.
8. Maffrand JP, Vallée E, Bernat A, Delebassée D, Miliou E, Tissinier A, Roncucci R. Animal pharmacology of PCR 4099, a new thienopyridine compound. Thromb Haemost 1985; 54: 789.
9. Reverter JC, Beguin S, Kessels R, Hemker HC, Coller BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. J Clin Invest 1996; 98: 863-74.
10. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb-IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997; 17: 528-35.
11. Altieri DC, Morrissey JH, Edgington TS. Adhesive receptor Mac-1 coordinates the activation of factor Xa on stimulated cells on monocytic and myeloid differentiation: An alternative initiation of the coagulation protease cascade. Proc Natl Acad Sci USA 1988; 85: 7462-6.
12. Altieri DC, Edgington TS. The saturable high affinity association of factor Xa to ADP-stimulated monocytes defines a novel function of the MAC-1 receptor. J Biol Chem 1988; 263: 7007-15.
13. Savi P, Badorc A, Lale A, Bordes MF, Bornia J, Labouret C, Bernat A, De Cointet P, Hoffmann P, Maffrand JP, Herbert JM. SR 121787, a new orally active fibrinogen receptor antagonist. Submitted for publication.
14. Hoffmann P, Bernat A, Savi P, Herbert JM. Antiplatelet and antithrombotic efficacy of SR 121787, a non-peptide orally active GpIIb/IIIa antagonist, in rabbits. Comparison to clopidogrel and aspirin. J Cardiovasc Pharm 1997, in press.
15. Born GV. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature (Lond.), 1962; 194: 927-9.
16. Beguin S, Lindhout T, Hemker HC. The effect of trace amounts of tissue factor on thrombin generation in platelet rich plasma, its inhibition by heparin. Thromb Haemost 1989; 61: 25-9.
17. Peyrou V, Lormeau JC, Hérault JP, Boneu B, Herbert JM. Long-term persistence of low molecular weight material with anti-factor Xa activity contributes to the anticoagulant and antithrombotic effects after subcutaneous injection of CY 216 in the rabbit. Blood Coag Fibrinol 1997; 8: 175-84.
18. Hemker HC, Wielders S, Kessels H, Beguin S. Continuous registration of thrombin generation in plasma, its use for the determination of the thrombin potential. Thromb Haemost 1993; 70: 617-24.
19. Herbert JM, Hérault JP, Bernat A, Van Amsterdam RGM, Vogel GMT, Lormeau JC, Petitou M, Meuleman DG. Biochemical and Pharmacological Properties of SANORG 32701 - Comparison with the "Synthetic pentasaccharide" (SR 90107/Org 31540) and Standard Heparin. Circ Res 1996; 79: 590-600.
20. Walenga JM, Petitou M, Lormeau JC, Samama M, Fareed J, Choay J. Antithrombotic activity of a synthetic heparin pentasaccharide in a rabbit stasis thrombosis model using different thrombogenic challenges. Thromb Res 1987; 46: 187-98.
21. Dol F, Gaich C, Bernat A, Mauran G, Herbert JM. Effect of clopidogrel on thrombin generation in the rat. Thromb Res 1992; 65: S160 (abst.).
22. Weiss HJ, Turitto VT, Baumgartner HG. Role of shear rate and platelets in promoting fibrin formation on rabbit subendothelium. Studies utilizing patients with quantitative and qualitative platelets defects. J Clin Invest 1986; 78: 1072-82.
23. Kessels H, Beguin S, Andree H, Henker HC. Measurement of thrombin generation in whole blood. The effect of heparin and aspirin. Thromb Haemost 1994; 72: 78-83.
24. Coller BS. Inhibitors of the platelet glycoprotein Ilb/IIIa receptor as a conjunctive therapy for coronary artery disease. Coron Artery Dis 1992; 3: 1016-29.
25. Cook NS, Kottirsch G, Zerwes HG. Platelet glycoprotein Ilb/IIIa antagonsist. Drug Future 1994; 19: 135-59.
26. Cadroy Y, Hanson SR, Andrews BK, Marzec UM, Evatt BL, Kunichi TJ, Montgomery RR, Harker LA. Relative antithrombotic effects of monoclonal antibodies targeting different platelet glycoprotein-adhesive molecule interactions in nonhuman primates. Blood 1994; 83: 3218-24.
27. Moliterno DJ, Califf RM, Aguire FV, Anderson K, Sigmon KN, Topol EJ. Effect of platelet GP IIb-IIIa integrin blockade on activated clotting time during percutaneous transluminal coronary angioplasty or directional atherectomy (the EPIC study). Am J Cardiol 1995; 87: 559-62.
28. Wessler S. Thrombosis in the presence of vascular stasis. Am J Med 1962; 33: 648-66.
29. Wessler S, Gitel SN, Bank H, Martinowitz U, Stephenson RC. An assay of the antithrombotic action of warfarin: its correlation with the inhibition of stasis thrombosis in rabbits. Thromb Haemost 1978; 40: 486-98.
30. Vogel GM, Meuleman DG, Bourgondien FG, Hobbelen PM. Comparison of two experimental thrombosis models in rats - effects of four glycosaminoglycans. Thromb Res 1989; 54: 399-410.